Multimechanistic Monoclonal Antibodies (MAbs) Targeting *Staphylococcus aureus* Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach

C. Tkaczyk, a S. Kasturirangan, a A. Minola, b O. Jones-Nelson, a V. Gunter, a Y. Y. Shi, a K. Rosenthal, a V. Aleti, a E. Semenova, a P. Warrener, a D. Tabor, a C. K. Stover, a D. Corti, b G. Rainey, a B. R. Sellman a

Medimmune LLC, Gaithersburg, Maryland, USA a; Humabs, Bellinzona, Switzerland b

ABSTRACT

Secreted alpha-toxin and surface-localized clumping factor A (ClfA) are key virulence determinants in *Staphylococcus aureus* bloodstream infections. We previously demonstrated that prophylaxis with a multimechanistic monoclonal antibody (MAb) combination against alpha-toxin (MEDI4893*) and ClfA (11H10) provided greater strain coverage and improved efficacy in an *S. aureus* lethal bacteremia model. Subsequently, 11H10 was found to exhibit reduced affinity and impaired inhibition of fibrinogen binding to ClfA002 expressed by members of a predominant hospital-associated methicillin-resistant *S. aureus* (MRSA) clone, ST5. Consequently, we identified another anti-ClfA MAb (SAR114) from human tonsillar B cells with 100-fold increased affinity for three prominent ClfA variants, including ClfA002, and potent inhibition of bacterial agglutination by 122 diverse clinical isolates. We next constructed bispecific Abs (BiSAbs) comprised of 11H10 or SAR114 as IgG scaffolds and grafted anti-alpha-toxin (MEDI4893*) single-chain variable fragment to the amino or carboxy terminus of the anti-ClfA heavy chains. Although the BiSAbs exhibited in vitro potencies similar to those of the parental MAbs, only 11H10-BiSAb, but not SAR114-BiSAb, showed protective activity in murine infection models comparable to the respective MAb combination. In vivo activity with SAR114-BiSAb was observed in infection models with *S. aureus* lacking ClfA. Our data suggest that high-affinity binding to ClfA sequesters the SAR114-BiSAb to the bacterial surface, thereby reducing both alpha-toxin neutralization and protection in vivo. These results indicate that a MAb combination targeting ClfA and alpha-toxin is more promising for future development than the corresponding BiSAb.

KEYWORDS

*Staphylococcus aureus*, alpha toxin, clumping factor A, monoclonal antibodies

Infections caused by antimicrobial-resistant (AMR) bacterial pathogens are an increasing threat to public health. The ongoing AMR epidemic has been fueled, in part, by empirical broad-spectrum antibiotic therapy (1). This has led to the exploration of pathogen-specific methods, including the use of monoclonal antibodies (MAbs), to prevent or treat serious bacterial infections. Numerous MAbs are currently in development for the prevention or treatment of antibiotic-resistant bacterial infections (2). Such passive immunization strategies provide an immediate and potent IgG response against the target pathogen. Ideally, the MAb, or MAb cocktail, provides multiple mechanisms of action to neutralize key bacterial virulence factors and augment the

Received 27 March 2017 Returned for modification 16 April 2017 Accepted 28 May 2017

Accepted manuscript posted online 5 June 2017

Citation Tkaczyk C, Kasturirangan S, Minola A, Jones-Nelson O, Gunter V, Shi YY, Rosenthal K, Aleti V, Semenova E, Warrener P, Tabor D, Stover CK, Corti D, Rainey G, Sellman BR. 2017. Multimechanistic monoclonal antibodies (MAbs) targeting *Staphylococcus aureus* alpha-toxin and clumping factor A: activity and efficacy comparisons of a MAb combination and an engineered bispecific antibody approach. Antimicrob Agents Chemother 61:e00629-17. https://doi.org/10.1128/AAC.00629-17.

Copyright © 2017 Tkaczyk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to B. R. Sellman, sellmanb@medimmune.com.
host innate immune response, thus providing the greatest opportunity for clinical success.

*Staphylococcus aureus* is a bacterial pathogen that causes a wide array of diseases, including skin and soft-tissue infections, endocarditis, osteomyelitis, pneumonia, and bacteremia (3). Preclinical results indicate MAb-based approaches hold promise for prophylaxis and adjunctive therapy against *S. aureus* infections (4–8). We previously reported that prophylaxis with a multimechanistic MAb combination targeting alpha-toxin (MEDI4893*) and clumping factor A (ClfA; 11H10) provided enhanced protection and improved strain coverage relative to the individual MAbs in an *S. aureus* lethal bacteremia model (9). A MAb combination such as this provides multiple mechanisms of action, including toxin neutralization, opsonophagocytic killing, and inhibition of fibrinogen binding and bacterial agglutination. Similarly, a MAb combination targeting *Pseudomonas aeruginosa* exopolysaccharide Psl and type 3 secretion system component PcrV provided enhanced protection relative to the individual MAbs in a *P. aeruginosa* acute pneumonia model (10) by mediating opsonophagocytic killing (OPK), blocking cell attachment, and inhibiting the injection of multiple virulence factors into target cells. These two examples provide support for multimechanistic MAb-based antibacterial treatment approaches.

An alternative approach to a MAb combination is to engineer both binding specificities into a single bispecific (BiS) or multispecific IgG molecule (11). The first BiS antibodies (BiSAbs) generated by somatic hybridization of two antibody-secreting cells were produced with poor yield due to random assembly of parental heavy and light chains (12). The discovery of single-chain variable fragments (scFvs) and advances in antibody engineering have opened new avenues for the development of BiS molecules (13, 14). There are now at least 50 different BiSAb formats based on scFv numbers and fusion positions on the IgG scaffold (15). One clear mechanistic advantage of a BiSAb can arise when binding of one specificity facilitates the binding and activity of the second specificity. This has been observed with the BiSAb MEDI3902, which targets the *P. aeruginosa* cell surface exopolysaccharide Psl and the tip of the type 3 secretion system injectisome, PcrV. In MEDI3902, the anti-Psl scFv was engineered into the hinge region of an anti-PcrV IgG1. Interestingly, this construct provided enhanced protection relative to the anti-PcrV–anti-Psl MAb combination in a *P. aeruginosa* acute pneumonia model (10). The improved activity was hypothesized to result from MEDI3902 high-avidity, lower-affinity binding to the abundant Psl polysaccharide around the bacterium, effectively increasing the concentration of the higher-affinity anti-PcrV MAb around the cell. Based on these results, we hypothesized that high-affinity binding of a BiSAb comprised of binding specificities for ClfA and alpha-toxin could increase the protective capacity of the MAb combination by localizing the anti-alpha-toxin specificity on the bacterial surface, better enabling the BiSAb to neutralize the toxin upon its secretion.

Here, we generated various BiSAbs containing anti-alpha-toxin and anti-ClfA activities. We determined that the anti-ClfA MAb 11H10 exhibited poor binding affinity for a predominant ClfA sequence type (ClfA002) and consequently generated a new anti-ClfA MAb, SAR114, with increased affinity for the three main ClfA sequence types (16). Anti-ClfA plus anti-alpha-toxin BiS molecules were comprised of 11H10 or SAR114 and an anti-alpha-toxin, MEDI4893*, and their relative potencies were compared *in vitro* and *in vivo*. Although the BiS molecules constructed from 11H10 and SAR114 retained the *in vitro* potency of the parental MAbs, the BiS molecules constructed from the higher-affinity anti-ClfA MAB SAR114 exhibited reduced protective activity *in vivo* relative to the MAb combination in *S. aureus* pneumonia and bacteremia models. In contrast, the *in vivo* activity of the 11H10 BiSAbs was comparable to that observed with the respective MAb combinations. Interestingly, SAR114-BiS protective activity was evident in mice challenged with an isogenic mutant defective for ClfA expression (SF8300ΔclfA), suggesting that SAR114 high-affinity binding to ClfA in the BiS molecule sequesters MEDI4893* on the bacterial surface, thereby preventing alpha-toxin neutralization. These results indicate that a BiSAb approach is not always superior to a MAb
combination, and appropriate platform selection requires rigorous preclinical studies in relevant animal models.

RESULTS

Characterization of anti-ClfA MAb SAR114. We previously reported on the enhanced protective capacity and isolate coverage afforded by prophylaxis with an anti-\textit{S. aureus} alpha-toxin MAb (MEDI4893) in combination with an anti-ClfA MAb (11H10) relative to the individual MAbs in an \textit{S. aureus} lethal bacteremia model (9). Although 11H10 is a potent anti-ClfA MAb, we found it exhibited a $1,000$-fold reduced affinity ($K_{on}$; below the limit of detection; ND in Table 1) and an $40$-fold increase in the $50\%$ inhibitory concentration (IC$_{50}$) for ClfA002 in the fibrinogen binding inhibition assay relative to ClfA001 and ClfA004 (Fig. 1A and Table 1). To increase potential clinical isolate coverage, we screened human tonsillar B cells to search for more broadly reactive anti-ClfA MAbs. From this effort, we identified a MAb (SAR114) with high affinity for ClfA001, ClfA002, and ClfA004 (apparent dissociation constant ($K_D$) of 1.15 to 44.7 pM) (Table 1) and potent inhibition of fibrinogen binding by these 3 prominent ClfA genotypes (IC$_{50}$ of 20 nM) (Fig. 1B). SAR114 also exhibited opsonophagocytic killing (OPK) activity against several \textit{S. aureus} clinical isolates (see Fig. S1 in the supplemental material) and improved inhibition of bacterial agglutination in human plasma compared to 11H10 (Fig. 1C; Fig. S2). SAR114 was found to compete for binding to ClfA001 by 11H10 to ClfA002 could not be determined (ND).

| Antibody and ClfA variant | Affinity$^a$ | Fibrinogen binding$^b$ |
|---------------------------|--------------|------------------------|
|                           | $K_{on}$ (M$^{-1}$ s$^{-1}$) | $K_{off}$ (s$^{-1}$) | $K_D$ (M) | IC$_{50}$ ($\mu$M) |
| SAR114                    |               |                       |           |                   |
| ClfA001                   | 2.41E+06      | 6.01E–06               | 2.49 pM   | 16.09             |
| ClfA002                   | 2.13E+06      | 9.53E–05               | 44.77 pM  | 6.004             |
| ClfA004                   | 5.62E+06      | 6.46E–06               | 1.15 pM   | 13.61             |
| 11H10                     |               |                       |           |                   |
| ClfA001                   | 1.09E+06      | 6.80E–03               | 6.22 nM   | 24.59             |
| ClfA002                   | ND           | 997.5                  |           |                   |
| ClfA004                   | 8.45E+05      | 6.39E–03               | 7.55 nM   | 23.94             |

$^a$Affinity constants ($K_D$) of SAR114 and 11H10 to the main ClfA variants were determined as the ratio between dissociation ($K_{off}$) and association ($K_{on}$) rate constants, as measured by Biacore. The affinity of SAR114 to ClfA002 was determined as the ratio between dissociation ($K_{off}$) and association ($K_{on}$) rate constants, as measured by Biacore. The affinity of 11H10 to ClfA002 could not be determined (ND).

$^b$In vitro activity of both anti-ClfA MAbs was measured in the fibrinogen binding inhibition assay for the main three ClfA variants and is expressed as IC$_{50}$.

**FIG 1** SAR114 MAb broad reactivity against the three main ClfA genotypes \textit{in vitro}. Inhibition of fibrinogen binding to the three main ClfA genotypes was measured in the presence of serially diluted (from 666 nM to 2.55 $\mu$M) anti-ClfA MAb 11H10 (A) or SAR114 (B). Data are representative of three independent experiments. C Agglutination of \textit{S. aureus} clinical isolates in the presence of human plasma. The graph shows the minimum concentration of 11H10 (■) and SAR114 (■) required to inhibit bacterial agglutination. Data are representative of two independent experiments. c-IgG, used as a negative control, did not show any inhibition at 200 $\mu$g/ml.
enzyme-linked immunosorbent assay (ELISA) and in an Octet-based competition assay (Fig. 2A and B). These results indicate the MAbs bind an overlapping epitope on ClfA001, suggesting their potency difference against ClfA002 results from different binding affinities.

**SAR114-MEDI4893** MAb combination provides broad strain coverage in lethal bacteremia. SAR114 protective activity next was evaluated in a murine lethal bacteremia model, alone and in combination with MEDI4893*. SAR114 (15 mg/kg) prophylaxis resulted in increased survival compared to an isotype control IgG (c-IgG) following challenge with *S. aureus* isolates representing ST8, ST5, or ST30, confirmed to encode ClfA genotypes ClfA001, ClfA002, and ClfA004, respectively (Table 2; Fig. S3). Similar to 11H10-MEDI4893*, prophylaxis with the SAR114-MEDI4893* combination (7.5 mg/kg each) significantly increased survival relative to c-IgG following challenge with all strains tested and provided a benefit over the individual MAbs against some strains (Table 2) (9). These results indicate SAR114 is functional in vivo and confirms the need for a MAb combination to provide broader strain coverage.

**Anti-alpha-toxin–anti-ClfA-bispecific MAb in vitro efficacy.** Passive immunization with an anti-ClfA–anti-alpha-toxin MAb combination provided a benefit for strain coverage in lethal bacteremia and retained the anti-alpha-toxin protective capacity in murine dermonecrosis and pneumonia models (9). To determine if a BiSAb comprised

***TABLE 2*** SAR114-MEDI4893* MAb combination strain coverage protection in lethal bacteremia

| Strain   | ST | Protection against lethal bacteremia by*: | SAR114 (15 mg/kg) | MEDI4893* (15 mg/kg) | Combination MAb (7.5 mg/kg each) |
|----------|----|----------------------------------------|-------------------|----------------------|----------------------------------|
| NRS123   | 1  | +                                      | +                 | +                    | +                                |
| ARC2784  | 188| +                                      | +                 | +                    | +                                |
| ARC635   | 5  | -                                      | +                 | +                    | +                                |
| NRS387   | 5  | +                                      | +                 | +                    | +                                |
| SF8300   | 8  | +                                      | +                 | +                    | +                                |
| NRS384   | 8  | -                                      | +                 | +                    | +                                |
| 3049057  | 8  | -                                      | -                 | -                    | +                                |
| 3049088  | 30 | +                                      | +                 | -                    | +                                |
| 3049114  | 30 | +                                      | +                 | -                    | +                                |

* A plus sign indicates significantly different from c-IgG (15 mg/kg) by log rank (Mantel-Cox) test.
of the anti-ClfA and anti-alpha-toxin MAb combinations, we engineered BiSAb molecules using 11H10 or SAR114 as the IgG backbones, to which the MEDI4893* scFv was appended to the amino (BiS2) or carboxy (BiS3) terminus of the heavy chain (Fig. 3) (19). The BiS2 and BiS3 formats were selected because the scFv is located in disparate locations on the IgG, and the only way to determine if one format has an advantage over another is to test them empirically for the antibody specificities of interest. To understand if the BiSAb molecules retained the functional activities of the individual MAb combinations, we measured the potency in inhibiting alpha-toxin-dependent rabbit red blood cell (RBC) lysis and inhibition of fibrinogen binding to ClfA001, ClfA002, and ClfA004. The 11H10-BiS2 and -BiS3 molecules and SAR114-BiS2 exhibited IC50s similar to that of MEDI4893* in an alpha-toxin hemolytic assay, whereas SAR114-BiS3 exhibited reduced alpha-toxin neutralization activity (Fig. 4A; Table S2). Both 11H10 BiSAb molecules and the SAR114 BiS3Ab exhibited IC50s similar to the respective parental anti-ClfA IgG in the fibrinogen binding inhibition assay, whereas the SAR114 BiS2Ab lost some activity against ClfA002 but was still superior to 11H10 (Fig. 4B; Fig. S4 and Table S2). The BiSAb molecules also mediated OPK similar to that of the parental anti-ClfA IgG (Fig. S5). Importantly, saturation of the anti-alpha-toxin scFv in the presence of a 10 M excess of alpha-toxin did not interfere with anti-ClfA activity in the fibrinogen binding assay (Fig. S5). Similar saturation of ClfA binding with a 10 M ClfA excess did not decrease alpha-toxin neutralizing activity of the BiSAb in the hemolytic assay (Fig. 4B; Table S2). Taken together, these results indicate the anti-alpha-toxin–anti-ClfA BiSAb molecules retain in vitro functional activity that in most cases was similar to that of the parental IgG, and this activity was not diminished in the presence of a 10-fold molar excess of the other antigen recognized by the BiSAb.

### Anti-alpha-toxin-anti-ClfA BiSAb molecule efficacy in lethal bacteremia.

The anti-ClfA–anti-alpha-toxin BiSAb protective activities next were compared to those of the MAb combinations in an S. aureus lethal bacteremia model. Mice were passively immunized with the MAb combinations (7.5 mg/kg or 1 mg/kg each) or equimolar doses of the BiSAb molecules (9 or 1.2 mg/kg, respectively) 24 h prior to intravenous (i.v.) infection with S. aureus SF8300, and survival was monitored for 14 days. Both SAR114-BiSAb molecules at 9 mg/kg exhibited reduced but not significantly different (P = 0.234 for BiS2 and P = 0.412 for BiS3) protection compared to the MAb combination at 7.5 mg/kg each (Fig. 5A). The MAb combination at 1 mg/kg (P = 0.0051 versus c-IgG) and SAR114-BiS2 at 1.2 mg/kg (P = 0.0336 versus c-IgG) significantly increased survival relative to c-IgG. Consistent with the observed loss of alpha-toxin neutralization activity in vitro (Fig. 4A), SAR114-BiS3 did not significantly increase survival when administered at 1.2 mg/kg (P = 0.657) (Fig. 5A). When tested against S. aureus strain 3049057 (MRSA, ST8), a strain where neither MAb alone is sufficient for significant protection (Fig. S3), the SAR114-BiS molecules at 1.2 mg/kg did not significantly increase survival relative to c-IgG (P = 0.4310), whereas an equimolar concentration (1 mg/kg) of the MAb
combination did (P = 0.0348 versus c-IgG) (Fig. 5B). This suggested a defect in the SAR114-BiS2Ab in vivo. Interestingly, passive immunization with the 11H10-BiS2Abs resulted in protection similar to that of the MAb combination at both doses (9 mg/kg and 1.2 mg/kg) and provided a significant increase in survival relative to c-IgG against both ClfA001-expressing strains, SF8300 and 3049057 (Fig. 5C and D). These results indicate that the anti-ClfA–anti-alpha-toxin BiSAbs do not provide benefit over the MAb combination, as was previously observed for the BiS4/H9251 PA (MEDI3902) against *P. aeruginosa*; rather, conversely, the SAR114–MEDI4893* BiS exhibited a loss in protection at lower doses against a strain where the individual MAbs are not sufficient to provide protection.

Binding to ClfA impairs BiSAb efficacy in lethal pneumonia. Since SAR114, in MAb or either BiS format, binds ClfA001-expressing strains, SF8300 and 3049057 (Fig. 5C and D). These results indicate that the anti-ClfA–anti-alpha-toxin BiSAbs do not provide benefit over the MAb combination, as was previously observed for the BiSαPA (MEDI3902) against *P. aerugi-nosa*; rather, conversely, the SAR114–MEDI4893* BiS exhibited a loss in protection at lower doses against a strain where the individual MAbs are not sufficient to provide protection.

### Binding to ClfA impairs BiSAb efficacy in lethal pneumonia.

Since SAR114, in MAb or either BiS format, binds ClfA001 with ~1,000-fold greater affinity than 11H10 (Tables 1 and 3), we hypothesized that its binding to ClfA sequesters the BiSAb on the bacterial surface, leading to poorer capture and neutralization of alpha-toxin as it is secreted. Alpha-toxin is a key virulence factor in *S. aureus* pneumonia (20), and passive immunization with an anti-alpha-toxin MAb alone protects mice from lethal *S. aureus* pneumonia (6, 8, 21). Moreover, we previously showed that the anti-ClfA MAb does not impact survival in the pneumonia model, and anti-alpha-toxin–anti-ClfA provides protection similar to that of anti-alpha-toxin alone (9). Therefore, to determine if the decreased protection observed with the SAR114-BiS2Abs in the lethal bacteremia model resulted from inadequate alpha-toxin neutralization, we examined SAR114-BiS efficacy in the lethal pneumonia model. Passive immunization with MEDI4893*
mg/kg) alone or in combination with SAR114 resulted in 100% protection following challenge with SF8300. However, passive immunization with SAR114-BiS2 or -BiS3 resulted in 30 and 0% survival, respectively (Fig. 6A). Interestingly, passive immunization with the 11H10-BiS2, which has /H110111,000-fold reduced affinity for ClfA (Table 1), provided 100% survival. These results support the conclusion that binding to ClfA on the bacterial surface sequesters SAR114-BiSAbs, thus impairing alpha-toxin neutralization. To further test this hypothesis, mice were passively immunized with the BiS2 molecules prior to intranasal (i.n.) infection with the SF8300Δclfa ClfA isogenic mutant.

**TABLE 3** SAR114- and 11H10-BiS molecule affinity to ClfA variants

| MAb and ClfA variant | Affinity to ClfA* |
|----------------------|-------------------|
|                      | $K_{on}$ (M⁻¹s⁻¹) | $K_{off}$ (s⁻¹) | $K_d$ |
| SAR114-BiS2          |                   |                 |       |
| ClfA001              | 1.04E+06          | 5.48E-06        | 5.283 pM |
| ClfA002              | 2.66E+06          | 9.69E-05        | 36.38 pM |
| ClfA004              | 3.16E+06          | 5.74E-06        | 1.815 pM |

| 11H10-BiS2          |                   |                 |       |
| ClfA001              | 1.79E+06          | 5.00E-02        | 424.3 nM |
| ClfA002              | ND                |                 |       |
| ClfA004              | 9.68E+04          | 4.00E-02        | 416.5 nM |

| SAR114-BiS3          |                   |                 |       |
| ClfA001              | 1.64E+06          | 1.56E-05        | 9.5 pM |
| ClfA002              | 1.85E+06          | 1.13E-04        | 61.1 pM |
| ClfA004              | 6.58E+05          | 3.40E-05        | 51.6 pM |

| 11H10-BiS3          |                   |                 |       |
| ClfA001              | 4.60E+05          | 2.37E-02        | 51.4 nM |
| ClfA002              | 4.35E+03          | 1.26E-03        | 289.9 nM |
| ClfA004              | 1.39E+05          | 5.63E-03        | 40.3 nM |

*The binding affinity constant ($K_d$) of BiS molecules to the three ClfA variants was measured by Biacore as the ratio between dissociation ($K_{off}$) and association ($K_{on}$) kinetic rate constants. ND, not determined.

**FIG 5** Efficacy for anti-Cifa MAb/MEDI4893* BiSAbs in i.v. bacteremia. BALB/c mice (n = 10) were passively immunized i.p. with SAR114/MEDI4893* BiS2, BiS3, or an SAR114-MEDI4893* combination at the indicated concentrations and were i.v. infected 24 h later with the LD₉₀ of SF8300 (6e7 CFU) (A) and 3049057 (5e7 CFU) (B). Protective efficacy for 11H10-MEDI4893* BiS2, BiS3, or 11H10-MEDI4893* MAbs was evaluated against SF8300 (C) or 3049057 (D) challenge. Survival was monitored for 2 weeks. Results were analyzed with a log rank (Mantel-Cox) test. Statistical analysis of results compared to those for c-IgG were considered statistically different at a $P$ value of <0.05 and are indicated with an asterisk. Data are representative of three independent experiments.
Prophylaxis with SAR114-BiSAb provided protection against the SF8300ΔclfA mutant similar to that of MEDI4893* (Fig. 6B). These results provide further evidence that SAR114-BiSAb binding to surface-localized ClfA prevents effective neutralization of soluble alpha-toxin.

DISCUSSION

*S. aureus* possesses a large arsenal of secreted and surface-expressed virulence factors, enabling it to cause a wide array of diseases, ranging from mild skin and soft-tissue infections to more severe and invasive diseases, such as pneumonia, osteomyelitis, and bloodstream infections (3). Differential expression of these virulence factors among clinical isolates and in different diseases presents a challenge when designing immunotherapeutic methods of treatment or prophylaxis and may be responsible in part for past clinical failures targeting individual *S. aureus* virulence determinants (22, 23). Therefore, immunotherapeutic strategies targeting multiple virulence pathways may block multiple pathogenic mechanisms and improve disease coverage, increasing the likelihood for clinical success (1, 24, 25).

Although alpha-toxin is a key virulence determinant in *S. aureus* pneumonia and skin and soft-tissue infections (20, 26), bloodstream infections are likely more complex, with a more complicated interplay of virulence determinants involved (27–31). Consistent with this hypothesis, prophylaxis with an anti-alpha-toxin IgG alone significantly reduced disease severity in *S. aureus* pneumonia and skin infection models in mice and rabbits (6, 8, 20, 21, 26, 32–34) but did not protect against challenge by all isolates tested in a lethal bacteremia model (Table 2) (9). However, passive immunization with MEDI4893* combined with anti-ClfA MAb 11H10 or SAR114 provided improved strain coverage, indicating that targeting multiple virulence factors may be necessary to protect against systemic *S. aureus* diseases such as bacteremia (Table 2; Fig. S3) (9).

ClfA is a fibrinogen-binding cell surface adhesin (35) that mediates bacterial agglutination and attachment to fibrinogen-coated surfaces and promotes complement evasion (36–40). Despite promising preclinical animal results with a limited number of strains (41, 42), an anti-ClfA MAb (tefibazumab [Aurexis]) and intravenous immunoglobulins (IVIG) enriched for high anti-ClfA titers (Veronate) failed to demonstrate a
protective effect in clinical testing (43, 44). This may have resulted from targeting a single virulence factor, differential expression among clinical isolates, or ClfA sequence variation (16, 45). Indeed, Brady et al. recently reported on ClfA sequence-dependent epitopes that generated antibody responses following vaccination with reduced affinity to ClfA001 versus ClfA002 (46). When the anti-CIFa MAb 11H10, generated against ClfA001, was tested for binding to the 3 founder ClfA sequences (ClfA001, ClfA002, and ClfA004), it bound similarly to ClfA001 and ClfA004 but exhibited an ~1,000-fold drop in affinity for ClfA002. This low affinity for ClfA002 resulted in a loss in functional activity (Fig. 1A and Table 1). However, this finding did not translate into a detectable loss of in vivo protection against the ClfA002-expressing ST5 strains tested (9). One possible explanation for this result is high-avidity binding on the bacterial surface compensating for a loss in MAb affinity for ClfA. Nevertheless, since ClfA002-expressing ST5/USA100 strains are frequently associated with bloodstream infections (47, 48), a campaign was initiated to identify a more broadly reactive high-affinity anti-CIFa MAb from human tonsillar memory B cells (49). The lead MAb identified from this campaign, SAR114, exhibited at least a 100-fold greater affinity for the 3 founder ClfA genotypes than 11H10 (Table 1), improved in vitro functional activity against ClfA002 (Fig. 1B) and ClfA002-expressing strains (Fig. 1C), and broad strain coverage in lethal bacteremia when combined with an anti-alpha-toxin MAb, MEDI4893 (Table 2; Fig. S3).

The benefits of MAb or vaccine antigen combinations over targeting individual antigens have also been reported for other pathogens. In fact, it was shown that combining MBAs with multiple mechanisms of action on a single BiSAb can provide improved protective activity not only over the individual MBAs but also the MAb combination (10, 50–52). In addition to the potential for improved efficacy of a BiSAb, a single-molecule approach could simplify Ab manufacturing (e.g., expression and purification) and overcome regulatory hurdles associated with clinical development of MAb combinations (10, 53). Here, anti-alpha-toxin–anti-CifA BiSAbs (except SAR114-BiS3, which lost some alpha-toxin-neutralizing activity) exhibited activity in vitro similar to that of the parental IgG1 MBAs (Fig. 4A and B); however, they provided no benefit over the MAb combinations in vivo, and the BiS molecules constructed with the higher-affinity anti-CifA MAb (SAR114) even lost protective activity relative to the MAb combination (Fig. 5A and B). This did not result from alpha-toxin or CifA simply competing for BiSAb binding, because the BiSAbs retained full activity in vitro in the presence of a 10-molar excess of either CifA or alpha-toxin (Fig. 4C and D). The in vivo activity loss likely resulted from SAR114 high-affinity binding to CifA sequestering the BiSAb on the bacterial surface, where it is apparently less effective at capturing and neutralizing alpha-toxin as it is secreted. This conclusion is supported by the finding that SAR114-BiS2Ab retained full alpha-toxin neutralization activity in mice infected with SF8300 lacking CifA (ΔclfA) (Fig. 6B).

In this work, we also compared the activity of two BiS constructs with different antibody pairs targeting the same antigens. The BiS constructs differed in that the anti-alpha-toxin scFv was fused to either the N (BiS2) or C terminus (BiS3) of the heavy chain. Both 11H10-BiS2 and -BiS3 molecules retained full anti-CifA and anti-alpha-toxin neutralizing activity. Alternatively, SAR114-BiS3 lost alpha-toxin-neutralizing activity, indicating that the best-performing BiS molecule in some cases is independent of antigen-specific scFv location. These results highlight the fact that IgG characteristics, such as antigen specificity, affinity, location, and distance between Fab and scFv, may not be used to predict BiSAb activity, but the best BiS format must be selected empirically for the individual IgG pairs. MEDI3902 is an example of an antibacterial BiSAb against P. aeruginosa that binds the abundant cell surface polysaccharides Psl and PcrV of the type 3 secretion system (T3SS). Like the anti-alpha-toxin–anti-CifA combination, MEDI3902 exhibits multiple mechanisms of action, including opsonophagocytic killing, anti-adherence activity (Psl), and inhibition of T3SS-mediated cytotoxicity. In contrast to the anti-CifA–anti-alpha-toxin BiSAbs, MEDI3902 exhibited improved T3SS neutralization activity in vitro and
increased protection in a murine pneumonia model relative to the MAb combination (10). The increased potency of MEDI3902 was hypothesized to result from its low-affinity binding to the highly abundant surface polysaccharide Psl, thereby increasing the local concentration and high-affinity binding and subsequent neutralization of the low-abundance surface target, PcrV (10). Such binding to two distinct surface antigens with differential affinities likely accounts for the improved activity seen with MEDI3902. In vitro and in vivo assays comparing efficacies between different BiS molecules, where anti-PcrV MAb is in Fab and anti-Psl is an scFv linked in N-terminal (BiS2), C-terminal (BiS3), and upper hinge (BiS4) region, between different BiS molecules, where anti-PcrV MAb is in Fab and anti-Psl is described previously (55). After 2 weeks, the culture supernatants were screened for the presence of alpha-toxin binding specificities on one BiSAb demonstrate no benefit over the MAb mixture, but also, when a high-affinity anti-ClfA MAb was used, the BiS showed reduced in vivo activity. This finding illustrates that a bispecific approach to a MAb combination cannot be universally applied to all antibacterial MAb combinations. The decision to use a MAb combination or a BiSAb is likely dependent on many factors, including antigen location (surface-expressed or secreted), antigen concentration or density, and relative MAb component binding affinities, along with developmental and regulatory concerns. This highlights the need to empirically determine the MAb format independently for each desired application.

**Materials and Methods**

**Bacterial strains.** Community-acquired MRSA SF8300 (USA300) and its isogenic ClfA deletion mutant (ΔclfA) were previously described (23). NRS strains were obtained from the Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA). ARC strains were obtained from the Astra Zeneca Research Collection, and strains identified with a number beginning with 304 were obtained from Eurofins. All strains and their corresponding multilocus sequence types (MLST) and ClfA genotypes are summarized in Table S1 in the supplemental material.

**Whole-genome sequencing and analysis.** DNA was purified from bacterial cultures via bead beating followed by extraction using a PureLink genomic DNA minikit (ThermoFisher). Sequencing libraries were prepared by Covaris mechanical shearing followed by a NEBNext Ultra DNA library preparation kit for Illumina (New England BioLabs Inc.). Sequencing was performed via MiSeq 2 × 250 runs (Illumina) with a targeted depth of 150-fold. Reads were de novo assembled (CLCBio Genomic Workbench 9.0.1), and clfA open reading frames were extracted and translated to protein sequences. ClfA protein alleles in the present study were matched to the allele numbering by Murphy et al. (16) by comparing all sequences (this study and GenBank accession numbers HQ424254 to HQ424312) to a common reference, USA300_FPR3757. MLSTs were determined using SRST2 (54) and the S. aureus MLST profiles (http://pubmlst.org).

**ClfA MAb generation.** Memory B cells were isolated from cryopreserved lymphocytes isolated from tonsils using phycoerythrin (PE)-Cy7-labeled CD19 microbeads (BD Biosciences), followed by staining with anti-PE beads (Miltenyi Biotec) and depletion of cells carrying IgM, IgD, and IgA by cell sorting on tonsils using phycoerythrin (PE)-Cy7-labeled CD19 microbeads (BD Biosciences), followed by staining with anti-PE beads (Miltenyi Biotec) and depletion of cells carrying IgM, IgD, and IgA by cell sorting on a FACSAria (BD Biosciences). Cells were immortalized under clonal conditions with Epstein-Barr virus as described previously (55). After 2 weeks, the culture supernatants were screened for the presence of ClfA001-specific MAb using a 384-well-based ELISA. Positive cultures were expanded in complete RPMI medium and selected for their ability to bind to ClfA genotypes 001, 002, and 004 with high affinity. The VH and VL sequences were retrieved by reverse transcription-PCR (RT-PCR).

**Cloning and expression of the ClfA variants.** ClfA sequences corresponding to the N2N3 domain (amino acids 221 to 559) of ClfA genotypes 001, 002, and 004 were obtained from GenBank (accession numbers HG424254, HQ424253, and HQ424257) (16). DNA encoding each sequence was codon optimized and subcloned into pET28a(+) with an AviTag biotinylation signal (GLNDIFEAQKIEWHE) cloned into the 5’ end of the clfA coding sequence and expressed in *Escherichia coli* BL21(DE3). Biotinylation was induced after cotransformation of BL21(DE3) cells with an isopropyl-β-D-thiogalactopyranoside (IPTG)-inducible plasmid containing the biA gene, encoding biotin ligase, and AviTag-ClfA containing pET28a(+) Recombinant proteins were purified from *E. coli* lysates using a HisTrap HP column (GE Healthcare) equilibrated with buffer A (25 mM sodium phosphate, pH 7.8, with 500 mM NaCl). The column was washed with buffer A followed by 1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-
propanesulfonate in buffer A for endotoxin removal. Impurities were removed with a 25 mM imidazole (Teknova) wash, and then CIFA was eluted with a linear gradient to 500 mM imidazole. The CIFA-containing fractions were pooled and dialyzed into Q buffer A (25 mM Tris, pH 7.5). The lysates were then loaded onto a 5-ml HiTrap Q Sepharose HP column (GE Healthcare) and eluted with a linear gradient to 500 mM NaCl. Fractions containing pure CIFA were dialyzed into 1× phosphate-buffered saline (PBS), pH 7.2, and aliquots were frozen at −80°C.

**Bispecific antibodies.** Bispecific antibodies were generated as previously described (11, 14). Briefly, anti-CIFA MAb 11H10 or SAR114 was used as the IgG scaffold, and MEDI4893* was grafted in scFv format. MEDI4893* scFv was synthesized in the VL-VH format with a 20-amino-acid (GGGGSx4) linker between the light and heavy variable domains (GeneArt, Life Technologies, IL). BisAbs were constructed by fusing MEDI4893* scFv sequences to the N terminus of the heavy chain of 11H10 or SAR114 anti-CIFA IgG1. Bis3 constructs were generated by appending the linker-scFv of MEDI4893* to the C terminus of the heavy chain of 11H10 or SAR114. BisAbs and Bis3 molecules were expressed by transient transfection in 293 cells, purified by protein A affinity chromatography, and polished by size exclusion chromatography. The integrity of each molecule was assessed by mass spectrometry and by intact mass and peptide mapping to verify proper formation of engineered and endogenous disulfide bonds.

**Hemolytic assay.** Rabbit red blood cell (RBC) hemolytic assay was performed as described previously (56). Briefly, serial dilutions of the BisAbs and MEDI4893* (500 to 1.7 nM) were mixed with alpha-toxin (0.1 μg/ml = 3 nM) and incubated with 50 μl of washed rabbit RBC (Peel Freeze) for 1 h at 37°C. In some assays, anti-alpha-toxin scFv of BisAb was saturated with a 10 M excess of CIFA (5 μM). Plates then were centrifuged at 1,200 rpm for 3 min, and 50 μl of supernatant was transferred to new plates. Nonspecific human IgG1 R347 was used as a negative control (c-IgG) (56). The optical density at 450 nm (OD450) was determined. R347, a human anti-gp120 MAb, was utilized as an isotype control human IgG1 (c-IgG).

**Competition binding.** Anti-CIFA MAbs 11H10 and SAR114 were tested in a competition assay for binding to ClfA genotypes ClfA001, ClfA002, and ClfA004 were measured by Biacore T200 instrument (GE Healthcare Life Sciences). A reference flow cell surface was also prepared using an IgG capture assay CM4 sensor chip with a final surface density of 500 resonance units (RUs) on the biosensor.

**Fibrinogen binding assay.** Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated overnight at 4°C with 2 μg/ml human fibrinogen (Sigma), washed 3× with PBS containing 0.1% Tween 20 (wash buffer), and blocked for 1 h at room temperature (RT) with 200 μl/well casein (Thermo Fisher). Following 3 washes, the plates were incubated for 1 h at room temperature with a mix of 50 μl AviTag ClfA221–559 (2 μg/ml) and serial dilutions of anti-CIFA MAb or BisAb in a 100-μl final volume of PBS. In some assays, anti-CIFA IgG1 of BisAb was saturated with a 10 M excess of alpha-toxin (6.6 mM). After washes, bound CIFA was detected using horseradish peroxidase (HRP)-conjugated streptavidin (1:20,000; GE Healthcare) and then 100 μl 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (KPL). The reaction was stopped after 10 min with 100 μl 0.2 M H2SO4. The OD450 on plates was read on a spectrophotometer.

**Agglutination inhibition in human plasma.** S. aureus clinical isolates were cultured overnight in Tryptic soy broth, washed in PBS, and suspended to one-tenth of the original volume in ice-cold PBS. Anti-CIFA MAbs or BisAbs were serially diluted (2-fold) in 30 μl PBS starting at 200 μg/ml and mixed with 30 μl of citrated human plasma in a 96-well U-bottom plate (Thermo Fisher Scientific). Bacteria were added (30 μl) and incubated for 5 min at 37°C. Each well was evaluated visually, and the lowest MAb concentration where bacteria agglutinated was recorded. R347, a human anti-gp120 MAb, was utilized as an isotype control human IgG1 (c-IgG).

**Opsonophagocytic killing assay.** HL-60 cells were obtained from ATCC (Manassas, VA), and OPK assay was conducted as previously described (9). Measurement of kinetic rate and binding constants by Biacore. Kinetic rate constants (Km and Kd) for binding of the anti-CIFA MAbs to CIFA genotypes CIFA001, CIFA002, and CIFA004 were measured using an IgG capture assay CM4 sensor chip with a final surface density of 500 resonance units (RUs) on a Biacore T200 instrument (GE Healthcare Life Sciences). A reference flow cell surface was also prepared using a CM4 sensor chip using the identical immobilization protocol without MAbs. Anti-CIFA MAbs were prepared at 25 nM (100 mM for Bis2-SAR114) in immobilization buffer (10 mM sodium acetate, pH 4), along with 3-fold serial dilutions of CIFA (0.009 nM to 20 nM for SAR114 and Bis2-SAR114; 0.91 to 2,000 nM CIFA001 and 2.28 to 5,000 nM CIFA002 and CIFA004 for 11H10 and Bis2-11H10) in instrument buffer (HBS-EP buffer; 0.01 M Hepes, pH 7.4, 0.15 M NaCl, 3 mM EDTA, and 0.005% P-20). Each concentration of CIFA was first injected over the immobilized MAbs and reference surfaces at a flow rate of 40 μl/min for 60 s. The resulting binding response curves yielded the association phase data. Following the injection of CIFA, the flow was then switched back to instrument buffer for 15 min (3 h for 2 highest concentrations of CIFA001) to permit collection of dissociation phase data, followed by a 1-min pulse of 10 mM glycine, pH 1.7, to regenerate the IgG-immobilized surface on the chip. Binding responses from duplicate injections of each concentration of CIFA were recorded for all MAbs. In addition, several buffer injections were interspersed throughout the injection series. Select buffer injections were used along with the reference cell responses to correct the raw data sets for injection artifacts and/or nonspecific binding interactions. Fully corrected binding data were then fit to a 1:1 binding model (Biacore T200 evaluation software, version 2.0, Biacore, Inc.) that included a term to correct for mass transport-limited binding, should it be detected. These analyses determined the kinetic rate constants Km and Kd, from which the apparent dissociation constant (Kp) was calculated as Kp = Km / Kd.

**Hemagglutination assay.** Anti-CIFA MAbs 11H10 and SAR114 were tested in a competition assay for binding to CIFA001 on an Octet RED96 system (FortéBio). Briefly, MAbs diluted at 5 μg/ml in PBS were captured on an aminopropylsilane (APS) biosensor for 7 min. Coated biosensors were moved into blocking buffer-containing wells (PBS, 1 mg/ml bovine serum albumin [Sigma]) for 6 min to block free sensor binding sites, subsequently incubated for 7 min with 2.5 μg/ml CIFA001 diluted in blocking buffer,
and finally moved into wells containing the competing MAbs diluted at 5 μg/ml in blocking buffer. Data were analyzed using the Octet data acquisition and analysis software. The absence of association of the competing MAbs resulted in competition and, thus, recognition of the same antigenic site, while noncompetition is obtained when association of the second MAb was detected.

Mouse models. All experiments were performed in accordance with institutional guidelines following experimental protocol review and approval by the Institutional Biosafety Committee (IBC) and the Institutional Animal Care and Use Committee (IACUC) at MedImmune.

Lethal bacteremia. Groups of 10–8 week-old female BALB/c mice (Harlan) were passively immunized by intraperitoneal (i.p.) injection of c-IgG, BiS molecules, or the anti-ClfA MAb–MEDI4893* combination and then challenged 24 h later by intravenous (i.v.) injection with the 90% lethal dose (LD90) of S. aureus isolate. Survival was monitored for 2 weeks. Statistical analysis of a specific antistaphylococcal antigen versus c-IgG was performed with a log rank (Mantel-Cox) test. Data were considered statistically different at a P value of <0.05, indicated with an asterisk.

Pneumonia. Female C57/B6 mice (Jackson) were injected i.p. with MEDI4893* isolate. Survival was monitored for 2 weeks. Statistical analysis versus c-IgG was performed with a log rank (Mantel-Cox) test. Data were considered statistically different at a P value of <0.05, indicated with an asterisk.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at https://doi.org/10.1128/AAC.00629-17.

SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.

REFERENCES

1. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.

2. DiGiandomenico A, Sellman BR. 2015. Antibacterial monoclonal antibodies: the next generation? Curr Opin Microbiol 27:78–85. https://doi.org/10.1016/j.mib.2015.07.014.

Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339:520–532. https://doi.org/10.1056/NEJM199802033390711.

4. Hazenbos WL, Kajihara KK, Vanderlin R, Morisaki JH, Lehar SM, Kwakkenbos MJ, Beaumont T, Bakker AQ, Phung Q, Swem LR, Ramakrishnan S, Kim J, Xu M, Shah IM, Diep BA, Sai T, Sebrell A, Khalfin Y, Oh A, Koth C, Lin SJ, Lee BC, Strandh M, Koefoed K, Andersen PS, Spits H, Brown EJ, Tan MW, Mariathasan S. 2013. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog 9:e1003653. https://doi.org/10.1371/journal.ppat.1003653.

5. Rouha H, Badarau A, Virasam ZC, Battles MB, Prinz B, Magyrics Z, Nagy G, Mirkina I, Stulik L, Zerbs M, Jagerhofer M, Maierhofer B, Teubenbacher A, Dolezelikova I, Gross K, Banjeee S, Zanzer G, Malafa S, Zmajkovic J, Maier S, Mabry R, Krauland E, Wittrup KD, Georg G, Tan MW, Mariathasan S. 2013. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog 9:e1003653. https://doi.org/10.1371/journal.ppat.1003653.

6. Folkert D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, Bee Wu C S, Pham A, Zeng P, Pons J, Rajpal A, Shelton D. 2013. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol 425:1641–1654. https://doi.org/10.1016/j.jmb.2013.02.008.

7. Karazujum H, Chen G, Aabandou L, Mahmoudieh M, Borouan AR, Shulenin S, Devi VS, Stavale E, Warfield KL, Zeitlin L, Roy CJ, Sidhu SS, Aman MJ. 2013. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog 9:e1003653. https://doi.org/10.1371/journal.ppat.1003653.

8. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O’Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58:3694–3702. https://doi.org/10.1128/AAC.02190-13.

9. Tkaczyk C, Hamilton MM, Sadowska A, Shi Y, Chang CS, Chowdhury P, Buonanpea R, Xiao X, Warrener P, Medavilla J, Kreiswirth B, Suzich J, Stover CK, Sellman BR. 2016. Targeting alpha toxin and ClfA with a multimechanistic monoclonal-antibody-based approach for prophylaxis of serious Staphylococcus aureus disease. mbio 7:e00528-16. https://doi.org/10.1128/mbio.00528-16.

10. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezbabh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK. 2014. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6:262ra155. https://doi.org/10.1126/scitranslmed.3009655.

11. Dimasi N, Gao C, Fleming C, Woods R RM, Yao XT, Shirinian L, Kiener PA, Wu H. 2009. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 393:672–692. https://doi.org/10.1016/j.jmb.2008.08.032.

12. Milestein C, Cuello AC. 1984. Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol Today 5:299–304. https://doi.org/10.1016/0167-5699(84)90155-5.

13. Orcutt KD, Ackerman ME, Cieslewicz M, Quirio E, Slursczyn AL, Frangioni JV, Wittrup KD. 2010. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 23:221–228. https://doi.org/10.1093/protein/gzp077.

14. Coloma MJ, Morrison SL. 1997. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15:159–163. https://doi.org/10.1038/nbt0297-159.

15. Kontermann RE. 2012. Dual targeting strategies with bispecific antibodies. MABS 4:182–197. https://doi.org/10.4161/mabs.4.2.19000.

16. Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, Hoiseth SK, Jansen KU, Anderson AS. 2011. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum Vaccin 7(Suppl):51–59. https://doi.org/10.4161/hv.7.0.14562.

17. Sharma-Kuinkel BK, Wu V, Tabor DE, Mok H, Sellman BR, Jenkins A, Yu L, Jafari HS, Rude TH, Ruffin F, Schell WA, Park LP, Yan Q, Thaden JT, Messina JA, Fowler VG Jr, Esser MT. 2015. Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and posturgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol 53:227–236. https://doi.org/10.1128/JCM.02023-14.

18. Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ, Jones RN. 2012. Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia. J Clin Microbiol 50:3694–3702. https://doi.org/10.1128/JCM.02024-12.

19. Byrne H, Conroy PJ, Whisstock JC, O’Kennedy RJ. 2013. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic appli-
22. Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, Stover CK, August 2017 Volume 61 Issue 8 e00629-17 aac.asm.org

31:2723–2730. 

37. McDevitt D, Nanavaty T, House-Pompes K, Bell E, Turner N, McIntire L, Foster T, Hook M. 1997. Characterization of the interaction between the Staphylococcus aureus clumping factor (CFA) and fibronectin. Eur J Biochem 247:416–424. https://doi.org/10.1111/j.1432-1033.1997.00416.x.

40. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus virulence determinants during colonization and disease. mBio 6:e00227-14. https://doi.org/10.1128/mBio.00227-14.

44. Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. 2016. Antibody-based biologics and their promise to combat Staphylococcus aureus infections. Trends Pharmacol Sci 37:231–241. https://doi.org/10.1016/j.tips.2015.11.008.

50. strangers-jonesyk, bae t, schneewind o. 2006. vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103:16042–16047. https://doi.org/10.1073/pnas.0606863103.

55. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050–1058. https://doi.org/10.1086/656043.

60. Powers ME, Becker RE, Sailer A, Turner JR, Bubeck Wardenburg J. 2015. Synergistic action of Staphylococcus aureus alpha-toxin on platelets and myeloid lineage cells contributes to lethal sepsis. Cell Host Microbe 17:775–787. https://doi.org/10.1016/j.chom.2015.05.011.

65. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J Infect Dis 206:352–356. https://doi.org/10.1086/651192.

70. McDevitt D, Nanavaty T, House-Pompes K, Bell E, Turner N, McIntire L, Foster T, Hook M. 1997. Characterization of the interaction between the Staphylococcus aureus clumping factor (CFA) and fibronectin. Eur J Biochem 247:416–424. https://doi.org/10.1111/j.1432-1033.1997.00416.x.

75. Hair PS, Echague CG, Sholl AM, Watkins JA, Geoghegan JA, Foster TJ, Cunnon KM. 2010. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun 78:1717–1727. https://doi.org/10.1128/IAI.00165-09.

80. Rasmussen RV, Fowler VG, Jr, Skov R, Bruun NE. 2011. Future challenges in combating Methicillin-resistant Staphylococcus aureus (MRSA) skin infections in vivo. Antimicrob Agents Chemother 55:511–518. https://doi.org/10.1128/AAC.02328-14.

85. DeJonge M, Burchfield D, Bloon B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F, Morris A, Kapik B, Roberson D, Kessler K, Patti J, Hetherington S. 2007. Clinical trial of safety and efficacy of NIH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151:260–265. https://doi.org/10.1016/j.jpeds.2007.04.060.

90. Weems JJ, Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JP, Cubin CJ, Talwani R, Moore T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG, Jr. 2006. Phase II randomized, double-blind, placebo-controlled study of safety and efficacy of NIH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151:260–265. https://doi.org/10.1016/j.jpeds.2007.04.060.

95. Rasmussen RV, Fowler VG, Jr, Skov R, Bruun NE. 2011. Future challenges in combating Methicillin-resistant Staphylococcus aureus (MRSA) skin infections in vivo. Antimicrob Agents Chemother 55:511–518. https://doi.org/10.1128/AAC.02328-14.

100. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J Infect Dis 206:352–356. https://doi.org/10.1086/651192.

105. Powers ME, Becker RE, Sailer A, Turner JR, Bubeck Wardenburg J. 2015. Synergistic action of Staphylococcus aureus alpha-toxin on platelets and myeloid lineage cells contributes to lethal sepsis. Cell Host Microbe 17:775–787. https://doi.org/10.1016/j.chom.2015.05.011.

110. McAdow M, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J Infect Dis 206:352–356. https://doi.org/10.1086/651192.

115. McAdow M, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J Infect Dis 206:352–356. https://doi.org/10.1086/651192.

120. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J Infect Dis 206:352–356. https://doi.org/10.1086/651192.

125. Prokai L, Nguyen V, Stover CK, Sellman BR. 2017. Targeting alpha toxin in Staphylococcus aureus vaccine development. Vaccine 35:2944–2949. https://doi.org/10.1016/j.vaccine.2017.04.046.

130. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, McAdow M, Missiakas DM, Schneewind O, Jansen KU, Anderson AS. 2009. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 27:3276–3280. https://doi.org/10.1016/j.vaccine.2009.01.062.

135. Brady RA, Mocca CP, Burns DL. 2013. Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants. Clin Vaccine Immunol 20:1338–1340. https://doi.org/10.1128/CVI.00275-13.

140. Rasmussen RV, Fowler VG, Jr, Skov R, Bruun NE. 2011. Future challenges in combating Methicillin-resistant Staphylococcus aureus (MRSA) skin infections in vivo. Antimicrob Agents Chemother 55:511–518. https://doi.org/10.1128/AAC.02328-14.

145. Corti D, Lanzavecchia A. 2014. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Microbiol Spectr 2:10.1128/microbiolspec.AID-00184-2014. https://doi.org/10.1128/microbiolspec.AID-00184-2014.

150. Chen W, Ying T, Dimitrov DS. 2013. Antibody-based candidate thera- peutics against HIV-1: implications for virus eradication and vaccine design. Expert Opin Biol Ther 13:657–671. https://doi.org/10.1517/14712598.2013.761969.

155. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE, Jr, Aman MJ, Dye JM, Lai JR, Chandran K. 2016. A “Trojan horse” bispecific antibody strategy for broad protection against ebolaviruses. Science 354:350–354. https://doi.org/10.1126/science.aag3267.

160. Laventie BJ, Rademaker HJ, Saleh M, de Boer E, Janssens R, Bourcier T, Subilia A, Marcellin L, van Haperen R, Lebbink JH, Chen T, Prevost G.
Grosveld F, Drabek D. 2011. Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins. Proc Natl Acad Sci USA 108:16404–16409. https://doi.org/10.1073/pnas.1102265108.

53. Corti D, Kearns JD. 2016. Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease. Curr Opin Immunol 40:51–61. https://doi.org/10.1016/j.coi.2016.03.001.

54. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zobel J, Holt KE. 2014. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. Genome Med 6:90. https://doi.org/10.1186/s13073-014-0090-6.

55. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875. https://doi.org/10.1038/nm1080.

56. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. 2012. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 19:377–385. https://doi.org/10.1128/CVI.00589-11.